Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines

J Zhai, C Li, B Sun, S Wang, Y Cui, Q Gao… - Bioorganic & Medicinal …, 2022 - Elsevier
Abstract Proteolysis Targeting Chimeras (PROTACs) based on multi-target inhibitors have
been reported several times recently. The advantages of PROTACs technology and the …

An F‐box protein attenuates fungal xylanase‐triggered immunity by destabilizing LRR‐RLP NbEIX2 in a SOBIR1‐dependent manner

N Wang, Z Yin, Y Zhao, J Wang, Y Pei, P Ji… - New …, 2022 - Wiley Online Library
Receptor‐like proteins (RLPs) lacking the cytoplasmic kinase domain play crucial roles in
plant growth, development and immunity. However, what remains largely elusive is whether …

Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells

B Hu, J Hu - Breast Cancer Research and Treatment, 2024 - Springer
Abstract Purpose Estrogen Receptor α (ERα) is a well-established therapeutic target for
Estrogen Receptor (ER)-positive breast cancers. Both Selective Estrogen Receptor …

Genetics, treatment, and new technologies of hormone receptor-positive breast cancer

W Sebastian, L Forchette, K Donoughe, Y Lun… - Cancers, 2023 - mdpi.com
Simple Summary In this review paper, we focused on the discussion of various important
aspects of hormone receptor (HR)-positive breast cancer, including HR structure and …

Therapeutic Consequences of Targeting the IGF-1/PI3K/AKT/FOXO3 Axis in Sarcopenia: A Narrative Review

B Gellhaus, KO Böker, AF Schilling, D Saul - Cells, 2023 - mdpi.com
The high prevalence of sarcopenia in an aging population has an underestimated impact on
quality of life by increasing the risk of falls and subsequent hospitalization. Unfortunately, the …

Phthalimide as a versatile pharmacophore scaffold: Unlocking its diverse biological activities

GFS Fernandes, JR Lopes… - Drug Development …, 2023 - Wiley Online Library
Phthalimide, a pharmacophore exhibiting diverse biological activities, holds a prominent
position in medicinal chemistry. In recent decades, numerous derivatives of phthalimide …

DDR1-targeted therapies: current limitations and future potential

D Wu, Z Ding, T Lu, Y Chen, F Zhang, S Lu - Drug Discovery Today, 2024 - Elsevier
Highlights•DDR1 plays a crucial role in regulating essential cellular physiological
activities.•Limitations of current DDR1 therapeutic approaches are discussed.•The reasons …

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma

S Pomella, SG Danielli, R Alaggio, WB Breunis… - Cancers, 2023 - mdpi.com
Simple Summary Rhabdomyosarcoma is the most common soft tissue cancer in children
and adolescents. Its resemblance to skeletal muscle tissue distinguishes …

Proteolysis-targeting chimera molecules targeting SHP2

D Yu, M Zheng, Y Liu, L Chen, H Li - Future Medicinal Chemistry, 2022 - Future Science
SHP2 is a member of the non-receptor protein tyrosine phosphatases, encoded by PTPN11,
and exhibits oncogenic activities. The close association between SHP2 and human cancer …

PROTACs: novel approach for cancer breakdown by breaking proteins

H Memon, BM Patel - Life Sciences, 2022 - Elsevier
Ubiquitination defects have been reported in various diseases, including neurodegenerative
diseases, metabolic disorders and cancer. Balance between degradation and synthesis of …